Navigation Links
Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300
Date:6/22/2013

insulin U300 during the study period compared to the Lantus® group (45.3% vs. 59.7%; RR 0.76; 95% CI 0.66 to 0.87). New insulin U300 was well-tolerated in this study, with no differences in other adverse events observed from Lantus®.

The EDITION I abstract is titled: New Insulin Glargine Formulation: Glucose Control and Hypoglycemia in People with Type 2 Diabetes Using Basal and Mealtime Insulin (EDITION I) (Riddle, MC et al) [Abstract no. 43-LB]EDITION II Topline results of EDITION II are consistent with EDITION I findings. EDITION II demonstrated that investigational new insulin U300 achieved similar blood sugar reduction while fewer patients experienced night-time low blood sugar events compared with Lantus®.

EDITION II evaluated efficacy and safety of new insulin U300 in a type 2 diabetes population (811 patients) treated with basal insulin plus oral antidiabetic therapy. The full EDITION II results will be submitted for presentation at upcoming scientific meetings.

"There remains a substantial unmet need in people with diabetes taking oral medication or insulin as many of them do not reach their glycemic goals," said Pierre Chancel, Senior Vice President, Global Diabetes, Sanofi. "With the investigational new insulin U300, we are striving to further enhance the clinical value of basal insulin, while building on the wealth of evidence of Lantus®, the world's most prescribed insulin."

About investigational new insulin U300Investigational new insulin U300 is a new formulation based on the glargine molecule, the biological entity of Lantus®, with its well established efficacy and safety profile. However, new insulin U300 has unique pharmacokinetic and pharmacodynamic profiles with studies demonstrating it has even flatter and more prolonged profiles than Lantus®.1,2 New insulin U300 also offers the benef
'/>"/>

SOURCE Sanofi
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
2. Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
3. Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
4. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
5. Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
6. Tolero Pharmaceuticals announces Worldwide Agreement with Sanofi for the In-license of Alvocidib (Flavopiridol)
7. NextBio Announces Translational Medicine Partnership with Sanofi
8. Hemodialysis Patient Share for Sanofis Ferrlecit Increased Significantly in the First Quarter of 2013 Compared to the Previous Quarter
9. Sanofi US Offers a New Way to Say "Thank You" and Recognize the Unsung Heroes of Severe Allergy Awareness
10. Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
11. Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , December 18, 2014 ... software application/module that is used to store, manipulate, ... RIS comprises a patient tracking and scheduling system, ... integration of RIS with HIS and other databases ... patient registration and patient scheduling, patient list management, ...
(Date:12/19/2014)... , Dec. 18, 2014  Decision Resources Group ... the United States will increase to a ... be primarily driven by expansion in the large direct ... devices will be increasingly adopted due to the advantages ... Other key findings from Decision Resources Group,s coverage ...
(Date:12/19/2014)... , Dec. 18, 2014 Since last month,s ... site now known as the leading online black market ... explosive growth in its offering of drugs and other ... show the takedowns did succeed in lowering the numbers ... review of the markets in August. But some new ...
Breaking Medicine Technology:The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 2The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 3U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 3
... Novelos Therapeutics, Inc. (OTCBB: NVLT) , a pharmaceutical company developing ... the pricing of an underwritten public offering of 9,840,000 units ... unit consists of one share of common stock and a ... will have an exercise price of $0.60 per share and ...
... Thirty years after the start of the HIV/AIDS epidemic, ... work tirelessly to bring relief and hope to those ... as the Foundation for Hospices in Sub-Saharan Africa, is ... those living with HIV/AIDS, focusing primarily on palliative care ...
Cached Medicine Technology:Novelos Therapeutics Prices $5.9 Million Public Offering 2Bringing Pain Management to Africa: Spreading Relief Through Training 2
(Date:12/17/2014)... A group of 127 scientists sent an ... reaction to a recent statement by the center that was ... derogated the efficacy of all brain exercises. , Signatories to ... of the center’s statement critical of brain exercise companies that ... overstated its case, in a document it had entitled “A ...
(Date:12/17/2014)... FL (PRWEB) December 17, 2014 No ... not been able to eradicate the head louse parasite—a ... hassle for parents. Each year between six and twelve ... Troopers, the Miami-based lice removal treatment company comes to ... non-toxic and environmentally friendly. With its track record of ...
(Date:12/17/2014)... Project Veritas is releasing a video interview of ... and Obamacare architect Jonathan Gruber to public attention. Award-winning ... which is being distributed on YouTube. , During the ... the Affordable Care Act in order to hide a ... per year tax grab. , “President Obama promised us ...
(Date:12/17/2014)... Mozes HealthDay Reporter , TUESDAY, ... infectious diseases, one worrisome phenomenon is when an illness that ... -- known as zoonosis -- is not uncommon and keeps ... an animal-borne disease might make inroads into the human population. ... -- and the culprits in this case were guinea pigs. ...
(Date:12/17/2014)... News) -- Poor students get more fruits and vegetables at ... But, the opposite is true for students from wealthier ... at school may give a healthy boost to poor students, ... the family income level, students all ate a similar amount ... The study was published recently in the journal Preventive ...
Breaking Medicine News(10 mins):Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 3Health News:Poor Students Eat Healthier Foods at School, Study Finds 2
... , , NASHVILLE, Tenn., ... and payment cycle management solutions for the healthcare industry, ... implemented the Emdeon Patient Responsibility Estimator(SM) solution. Emdeon Patient ... BroMenn,s patient access staff to inform patients of their ...
... , , PISCATAWAY, ... Board: MLSS), the recognized leader in advanced injection technologies, ... Office has issued a Notice of Allowance for Milestone,s ... disposable hand piece for fluid administration. Milestone,s proprietary, ...
... , , WACO, Texas, Aug. 24 ... out a universal health care plan in their new book ... published by Cambridge University Press, that does not create a ... coverage or health care of Americans who currently have coverage. ...
... , BERKELEY HEIGHTS, N.J., Aug. 24 Authentidate ... of secure Health Information Exchange and workflow management services, today ... of home healthcare services and medical equipment, selected Authentidate,s Inscrybe(TM) ... physicians. , , "We believe that Inscrybe ...
... Boost Your Local Blood Supply , , ... its regional operations in Manhattan, Long Island, Hudson Valley, Brooklyn / ... blood now through Labor Day to help ensure that your community ... NYBC also asks that people who have donated blood once in ...
... , , ... Inc., announced today that it has received European CE Mark ... System. The device is now approved for use in improving ... disease. , , The novel vProtect(TM) Luminal ...
Cached Medicine News:Health News:Emdeon and BroMenn Healthcare System Take the Lead on Consumer Price Transparency 2Health News:Emdeon and BroMenn Healthcare System Take the Lead on Consumer Price Transparency 3Health News:Emdeon and BroMenn Healthcare System Take the Lead on Consumer Price Transparency 4Health News:Milestone Scientific Announces Notice of Allowance From US Patent and Trademark Office 2Health News:Milestone Scientific Announces Notice of Allowance From US Patent and Trademark Office 3Health News:Baylor University Economists Call for Different Tack on Health Care Insurance 2Health News:LifeCare Solutions Simplifies Healthcare Order Process Management with Authentidate's Inscrybe Healthcare 2Health News:LifeCare Solutions Simplifies Healthcare Order Process Management with Authentidate's Inscrybe Healthcare 3Health News:LifeCare Solutions Simplifies Healthcare Order Process Management with Authentidate's Inscrybe Healthcare 4Health News:Give Blood Today for Community Preparedness 2Health News:Give Blood Today for Community Preparedness 3Health News:vProtect Luminal Shield (TM) from Prescient Medical Receives CE Mark 2
... Chemstrip Micral test strips are an ... in urine samples. When the test ... sample, urine passes via a wick ... albumin present in the sample binds ...
The A350 test is used for POC testing in hospital emergency departments, replacing the need to draw blood for alcohol testing. Each hash mark is 0.02% or 20 mg/dL....
AccuSign DOA Series tests include tests for Amphetamines, Barbituates, Benzodiazepines, Cocaine, Methadone, Methamphetamines, Nicotine (Cotinine), Opiates, Phencyclidine, THC, Tricyclic Antidepressan...
... drugs of abuse tests are highly accurate in ... recommended cut-off as confirmed by GC/MS testing. This ... specific alternative method (such as GC/MS) must be ... Professional judgment should be applied to any drug ...
Medicine Products: